Skip to main content
. 2014 May 20;2014:702701. doi: 10.1155/2014/702701

Table 3.

Patient's characteristics among positive and negative anti-IFX antibodies.

Positive anti-IFX antibodies Negative anti-IFX antibodies P value
Disease duration, mean, and months 90.77 ± 49.56 128 ± 97.48 0.306
IFX treatment duration, mean, and months 29.77 ± 17.01 38.77 ± 34.60 0.511
DAS28 at flare and mean 5.09 ± 1.19 4.18 ± 1.67 0.189
DAS28 after 2 months and mean 5.68 ± 0.8 3.95 ± 1.49 0.006
csDMARD association and nr (%) 3 9 0.028

Differences between patient's characteristics were tested by Student's t-test or chi-square test.

IFX: infliximab; csDMARD: conventional synthetic disease modifying antirheumatic drug.